Join
Live feed
·
PRReleasevia Quantisnow
Longeveron Inc. logo

Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer's Association International Conference (AAIC)

ByQuantisnow·Wall Street's wire, on your screen.
LGVN· Longeveron Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LGVN (Longeveron Inc.) and more on Quantisnow.